Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Chinese Patent Office
Boehringer Ingelheim
Merck
Daiichi Sankyo
US Department of Justice
Mallinckrodt
Moodys
Healthtrust

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,947,681

« Back to Dashboard

Which drugs does patent 7,947,681 protect, and when does it expire?

Patent 7,947,681 protects KUVAN and is included in one NDA.

Protection for KUVAN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-four patent family members in eighteen countries.
Summary for Patent: 7,947,681
Title:Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
Abstract: The present invention is directed to treatment methods of administering tetrahydrobiopterin, including in oral dosage forms, in intravenous formulations, and with food. Also disclosed herein are biopterin assays for measuring the amount of biopterin and metabolites of biopterin in a sample.
Inventor(s): Oppenheimer; Daniel I. (Castro Valley, CA), Dorenbaum; Alejandro (Mill Valley, CA), Okhamafe; Augustus (Concord, CA), Foehr; Erik (San Rafael, CA), Castillo; Sianna (San Francisco, CA), Kostel; Paul J. (Santa Rosa, CA)
Assignee: Biomarin Pharmaceutical Inc. (Novato, CA)
Application Number:12/577,509
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,947,681
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,947,681

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Biomarin Pharm KUVAN sapropterin dihydrochloride TABLET;ORAL 022181-001 Dec 13, 2007 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,947,681

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,324,210 Pterin analogs ➤ Try a Free Trial
7,475,360 Method for dynamically providing scroll indicators ➤ Try a Free Trial
RE43797 Methods of administering tetrahydrobiopterin ➤ Try a Free Trial
7,612,073 Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,947,681

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2008240259 ➤ Try a Free Trial
Australia 2008347005 ➤ Try a Free Trial
Brazil PI0809470 ➤ Try a Free Trial
Brazil PI0821970 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
QuintilesIMS
Farmers Insurance
Cipla
Covington
Boehringer Ingelheim
US Army
Julphar
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.